Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation
Phase of Trial: Phase IV
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms REASSURE
- Sponsors Bayer
- 12 Sep 2017 First interim analysis results (n=583) presented at the 42nd European Society for Medical Oncology Congress
- 01 Sep 2017 According to a Bayer media release, first interim results will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
- 22 Aug 2017 Planned number of patients changed from 1334 to 1440.